ESMO VIRTUAL ADVANCED COURSE PROGRAMME
INNOVATION AND EMERGING KNOWLEDGE IN
COLORECTAL CANCER
13-14 January 2022

CO-CHAIRS: Elena Élez, Spain
             Julien Taieb, France

SPEAKERS:  Jean-Baptiste Bachet, France
           Fortunato Ciardiello, Italy
           Holger Heyn, Spain
           Erika Martinelli, Italy
           Clara Montagut, Spain
           Filippo Pietrantonio, Italy
           Andrea Sartore-Bianchi, Italy
           Jenny Seligmann, United Kingdom

LEARNING OBJECTIVES

- To learn the biological basis and characterization of Colorectal Cancer (CRC)
- To understand the essentials in the assessment and the value of multidisciplinary management of patients with CRC
- To learn how to integrate and to sequence the available therapies in the management of a patient with advanced CRC
- Integrating molecular and clinical information including direct exposure to real clinical scenarios
- To learn and discuss about future advances in diagnose and treatment of CRC

ACCREDITATION

The programme of this event will be accredited with ESMO-MORA category 1 points.
Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from

SERVIER

ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4
6900 Lugano
Switzerland
Email: courses@esmo.org
www.esmo.org
Programme timings are to be considered CET (Central European Time)

**Thursday, 13 January 2022**

**15:00-15:05** Welcome and course overview
5’ Elena Élez, ES and Julien Taieb, FR

**15:05-16:00** Session 1 – Biological basis and characterization of CRC
15’ Genomic characterization of CRC
Andrea Sartore-Bianchi, IT
15’ The relevance of stroma in CRC
Filippo Pietrantonio, IT
15’ Tumor heterogeneity and clonal evolution as a hallmark in CRC
Clara Montagut, ES
10’ Discussion
Faculty

**16:00-16:55** Session 2 – Therapeutic approach in the early disease
15’ Optimizing perioperative treatment in rectal cancer
Jean-Baptiste Bachet, FR
15’ Is there a room for neoadjuvant treatment in colon cancer?
Jenny Seligmann, UK
15’ ctDNA in the early stage: evidence and strategies
Clara Montagut, ES
10’ Discussion
Faculty

**16:55-17:05** Virtual break

**17:05-18:00** Session 3 – The continuum of care of mCRC: managing specific situations
15’ State-of-the-art treatment of left sided RAS/BRAF native CRC. Must we consider and assess clonal evolution?
Jean-Baptiste Bachet, FR
15’ Maintenance treatment in CRC: new evidence
Jenny Seligmann, UK
15’ New treatment options for refractory CRC
Erika Martinelli, IT
10’ Discussion
Faculty

**18:00-18:30** Keynote lecture
25’ Potentials of single cell sequencing in cancer research: focus on CRC
Holger Heyn, ES

5’ Discussion
Faculty
**Friday, 14 January 2022**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:00-16:15</td>
<td><strong>Session 4 – Novel therapies</strong></td>
</tr>
</tbody>
</table>
| 15’      | The arena of HER2 in mCRC: when, how and new treatment options  
Andrea Sartore-Bianchi, IT |
| 15’      | Targeting the MAP kinase pathway in CRC  
Elena Élez, ES |
| 15’      | MSI-H/dMMR mCRC: understanding the profile of response  
Julien Taieb, FR |
| 15’      | Treatment strategies in MSS/pMMR mCRC  
Filippo Pietrantonio, IT |
| 15’      | Discussion  
Faculty |
| 16:15-16:45 | **Professional development session** |
| 25’      | How to build an efficient career path: identifying the key stakeholders  
Fortunato Ciardiello, IT |
| 5’       | Discussion  
Faculty |
| 16:45-16:55 | **Virtual break** |
| 16:55-18:15 | **Workshop sessions (all 60 delegates will attend all workshops, one after the other)** |
| 10’      | Introduction of the topic on real examples presented by speakers  
Discussion |
| 16:55-17:35 | **Workshop 1** |
| 40’      | Management of oligometastatic disease  
Jean-Baptiste Bachet, FR and Erika Martinelli, IT |
| 17:35-18:15 | **Workshop 2** |
| 40’      | Innovative trial designs in advanced CRC  
Filippo Pietrantonio, IT and Jenny Seligmann, UK |
| 18:15-18:30 | **Synthesis and wrap-up** |
| 15’      | Elena Élez, ES and Julien Taieb, FR |